-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of CDE showed that CSPC’s Class 1 new drug SYHX2001 tablet was approved for clinical use and is intended to be used for the treatment of advanced malignant solid tumors
.
Since the beginning of this year, CSPC has received 13 Class 1 new drugs approved for clinical trials in China
.
.
Since the beginning of this year, CSPC has received 13 Class 1 new drugs approved for clinical trials in China
.
CSPC's Class 1 new drug SYHX2001 tablet was first declared for IND at the end of October this year, and obtained the implied license for clinical trials on December 24, which is intended to be used for the treatment of advanced malignant solid tumors
.
.
Anti-tumor drugs are a hot research and development area, and their market size is also increasing year by year
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 10.
69%; 2021H1 sales Over 57 billion yuan, an increase of 17.
74% year-on-year
.
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 10.
69%; 2021H1 sales Over 57 billion yuan, an increase of 17.
74% year-on-year
.
Chemical sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
As a leading comprehensive pharmaceutical company in China , CSPC has adhered to the innovation and transformation strategy in recent years and has continued to increase R&D investment
.
In the first three quarters of 2021, CSPC’s R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With substantial investment, CSPC's innovation pipeline research and development progress has continued
.
.
In the first three quarters of 2021, CSPC’s R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With substantial investment, CSPC's innovation pipeline research and development progress has continued
.
Since 2021, CSPC has received clinical approval for 13 new class 1 drugs, including small molecule chemical drugs SYHX2001 tablets, SKLB1028 capsules, SYHA1402 tablets, SYHX1901 tablets, SYHX1903 tablets, SYHA1811 tablets and macromolecular biological drugs NBL-015 injection , NBL-012 injection, JMT601 injection, SYSA1801 injection, TG103 injection and the like
.
.
Since 2021, CSPC has been approved as a domestic clinical Class 1 new drug
13 new class 1 drugs involve major targets such as CLDN18.
2, JAK, BTK, PD-1, CDK9, among which there are two new drugs targeting CLDN18.
2
.
In terms of indications, CSPC focuses on the field of tumor treatment
.
2, JAK, BTK, PD-1, CDK9, among which there are two new drugs targeting CLDN18.
2
.
In terms of indications, CSPC focuses on the field of tumor treatment
.
In addition, CSPC has 4 new drugs approved for clinical use in the United States this year, including NBL-015, JMT601, NBL-012, SYSA1801
.
Among them, the Phase 1/2 clinical trial of JMT601 has been administered to the first patient in the United States
.
.
Among them, the Phase 1/2 clinical trial of JMT601 has been administered to the first patient in the United States
.
Data source: Minet database, CDE
Recently, the official website of CDE showed that CSPC’s Class 1 new drug SYHX2001 tablet was approved for clinical use and is intended to be used for the treatment of advanced malignant solid tumors
.
Since the beginning of this year, CSPC has received 13 Class 1 new drugs approved for clinical trials in China
.
.
Since the beginning of this year, CSPC has received 13 Class 1 new drugs approved for clinical trials in China
.
CSPC's Class 1 new drug SYHX2001 tablet was first declared for IND at the end of October this year, and obtained the implied license for clinical trials on December 24, which is intended to be used for the treatment of advanced malignant solid tumors
.
.
Anti-tumor drugs are a hot research and development area, and their market size is also increasing year by year
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 10.
69%; 2021H1 sales Over 57 billion yuan, an increase of 17.
74% year-on-year
.
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 10.
69%; 2021H1 sales Over 57 billion yuan, an increase of 17.
74% year-on-year
.
Chemical sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
As a leading comprehensive pharmaceutical company in China , CSPC has adhered to the innovation and transformation strategy in recent years and has continued to increase R&D investment
.
In the first three quarters of 2021, CSPC’s R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With substantial investment, CSPC's innovation pipeline research and development progress has continued
.
.
In the first three quarters of 2021, CSPC’s R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With substantial investment, CSPC's innovation pipeline research and development progress has continued
.
Since 2021, CSPC has received clinical approval for 13 new class 1 drugs, including small molecule chemical drugs SYHX2001 tablets, SKLB1028 capsules, SYHA1402 tablets, SYHX1901 tablets, SYHX1903 tablets, SYHA1811 tablets and macromolecular biological drugs NBL-015 injection , NBL-012 injection, JMT601 injection, SYSA1801 injection, TG103 injection and the like
.
.
Since 2021, CSPC has been approved as a domestic clinical Class 1 new drug
13 new class 1 drugs involve major targets such as CLDN18.
2, JAK, BTK, PD-1, CDK9, among which there are two new drugs targeting CLDN18.
2
.
In terms of indications, CSPC focuses on the field of tumor treatment
.
2, JAK, BTK, PD-1, CDK9, among which there are two new drugs targeting CLDN18.
2
.
In terms of indications, CSPC focuses on the field of tumor treatment
.
In addition, CSPC has 4 new drugs approved for clinical use in the United States this year, including NBL-015, JMT601, NBL-012, SYSA1801
.
Among them, the Phase 1/2 clinical trial of JMT601 has been administered to the first patient in the United States
.
.
Among them, the Phase 1/2 clinical trial of JMT601 has been administered to the first patient in the United States
.
Data source: Minet database, CDE
Recently, the official website of CDE showed that CSPC’s Class 1 new drug SYHX2001 tablet was approved for clinical use and is intended to be used for the treatment of advanced malignant solid tumors
.
Since the beginning of this year, CSPC has received 13 Class 1 new drugs approved for clinical trials in China
.
.
Since the beginning of this year, CSPC has received 13 Class 1 new drugs approved for clinical trials in China
.
CSPC's Class 1 new drug SYHX2001 tablet was first declared for IND at the end of October this year, and obtained the implied license for clinical trials on December 24, which is intended to be used for the treatment of advanced malignant solid tumors
.
.
Anti-tumor drugs are a hot research and development area, and their market size is also increasing year by year
.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 10.
69%; 2021H1 sales Over 57 billion yuan, an increase of 17.
74% year-on-year
.
Hospital hospital hospital tumor tumor tumor.
Meters within the network data show that in 2020 China's urban public hospitals , county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal anti -tumor drug sales exceeded 100 billion yuan, an increase of 10.
69%; 2021H1 sales Over 57 billion yuan, an increase of 17.
74% year-on-year
.
Chemical sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
As a leading comprehensive pharmaceutical company in China , CSPC has adhered to the innovation and transformation strategy in recent years and has continued to increase R&D investment
.
In the first three quarters of 2021, CSPC’s R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With substantial investment, CSPC's innovation pipeline research and development progress has continued
.
Enterprise business enterprise.
In the first three quarters of 2021, CSPC’s R&D expenses were 2.
508 billion yuan, a year-on-year increase of 10.
67%
.
With substantial investment, CSPC's innovation pipeline research and development progress has continued
.
Since 2021, CSPC has received clinical approval for 13 new class 1 drugs, including small molecule chemical drugs SYHX2001 tablets, SKLB1028 capsules, SYHA1402 tablets, SYHX1901 tablets, SYHX1903 tablets, SYHA1811 tablets and macromolecular biological drugs NBL-015 injection , NBL-012 injection, JMT601 injection, SYSA1801 injection, TG103 injection and the like
.
.
Since 2021, CSPC has been approved as a domestic clinical Class 1 new drug
13 new class 1 drugs involve major targets such as CLDN18.
2, JAK, BTK, PD-1, CDK9, among which there are two new drugs targeting CLDN18.
2
.
In terms of indications, CSPC focuses on the field of tumor treatment
.
2, JAK, BTK, PD-1, CDK9, among which there are two new drugs targeting CLDN18.
2
.
In terms of indications, CSPC focuses on the field of tumor treatment
.
In addition, CSPC has 4 new drugs approved for clinical use in the United States this year, including NBL-015, JMT601, NBL-012, SYSA1801
.
Among them, the Phase 1/2 clinical trial of JMT601 has been administered to the first patient in the United States
.
.
Among them, the Phase 1/2 clinical trial of JMT601 has been administered to the first patient in the United States
.
Data source: Minet database, CDE
